Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Immuno-Oncology's Next Wave: Key Targets And Emerging Players

Jun 02 2016

• By Mandy Jackson

Related Content

Scrip's Rough Guide to Immuno-Oncology

Jun 01 2015

Merck, AZ, Roche, BMS work off grid for mix-and-match immuno-oncology

Jun 12 2015

Sanofi plays catch-up in immuno-oncology with new Regeneron deal

Jul 28 2015

Incyte, Hengrui In 'Biggest Ever' China Pharma Out-Licensing Deal

Sep 04 2015

Amgen's Imlygic 1st FDA-Approved Oncolytic Virus Therapy

Oct 28 2015

Incyte and Merck Push I/O Drug Forward

Oct 14 2015

Valeant ups bid for Dendreon's Provenge to $400m

Feb 06 2015

Aduro shows survival benefit with pancreatic cancer vaccine duo

Jan 16 2014

JPM Parting Shots: Immuno-Oncology Plans For Regeneron, Incyte, Molecular Partners

Feb 16 2016

ARMO Rides Immuno-Oncology Wave With $50m For Its PD-1 Booster

Feb 17 2016

Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected

Apr 28 2016

Ten Programs To Watch Out For At ASCO

May 20 2016

Stockwatch: Fireworks Or Ballistic Missiles In Biotechnology?

May 23 2016

Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market

May 19 2016

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

Genentech, Inc.

AstraZeneca PLC

Pfizer Inc.

Merck KGaA

Bristol Myers Squibb Company

Novartis AG

Amgen, Inc.

Dendreon Corporation

Bausch Health Companies Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

Incyte Corporation

Jiangsu Hengrui Pharmaceuticals

Aduro Biotech, Inc.

ARMO BioSciences, Inc.

Additional Topics

Companies Cancer

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window